# Andrew Bayliffe

> Andrew Bayliffe is a Series A investor at Apple Tree Partners (London) backing Health Care. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Apple Tree Partners](https://shizune.co/investors/profile/apple-tree-partners)
- Location: London, United Kingdom
- Total investments: 2
- Last investment: Nov 2021
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/andrew-bayliffe-361a17161/

Andrew Bayliffe is a venture partner at ATP. With more than 20 years of leadership experience in the biopharmaceutical industry, he possesses expertise in the discovery and development of both small molecule and antibody therapeutics across a broad range of diseases areas. Most recently, at GlaxoSmithKline (GSK), he served as head of the Fibrosisand Lung Injury Discovery unit at GSK’s R&D headquarters in Stevenage, UK, and held senior roles in antibody discovery and development in the US and UK.Andrew is an honorary professor at the Wolfson Institute of Experimental Medicine at Queens College in Belfast. He completed his undergraduate and PhD studies in pharmacology, physiology, and molecular biology at Manchester University and Leeds University in the UK.

## Investment focus

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 50% |
| Series B | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Marengo Therapeutics | Marengo Therapeutics is seeking professionals who are motivated to make a positive difference in patients’ lives. | $80M | Series A | Nov 08, 2021 |  |
| Marengo Therapeutics | Marengo Therapeutics is seeking professionals who are motivated to make a positive difference in patients’ lives. | $80M | Series B | Nov 08, 2021 |  |

2 of 2 investments shown.

## About Apple Tree Partners

VC Fund · New York, United States

ATP, a global leader in life sciences venture capital, is developing the next generation of transformative biotechnology companies. ATP creates science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines. The firm provides flexible capital, strategicinsight, and operational resources to build sustainable, research-driven enterprises. ATP invests in its portfolio companies from seed stage through IPO and beyond and supports their management teams in strategic transactions and synergistic business combinations.

5 contacts available at Apple Tree Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Alexander McCampbell | Venture Partner | https://shizune.co/investors/profile/alexander-mccampbell |
| Andrew Bayliffe | Venture Partner | https://shizune.co/investors/profile/andrew-bayliffe |
| Anna Batarina | Partner | https://shizune.co/investors/profile/anna-batarina |
| Brian Vash | Entrepreneur in Residence | https://shizune.co/investors/profile/brian-vash |
| Daniel Finkelman | General Counsel | https://shizune.co/investors/profile/daniel-finkelman-9525 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Andrew Bayliffe invest in?

Andrew Bayliffe invests primarily in Health Care startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Andrew Bayliffe last invest?

The most recent investment recorded for Andrew Bayliffe closed in Nov 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co